Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Alligator Bioscience AB

www.alligatorbioscience.se

Latest From Alligator Bioscience AB

J&J Drops Alligator’s MAb ADC-1013 After Reviewing Combination Data

The anti-CD40 antibody underperformed in some preclinical cancer combination studies, leading J&J to prioritize other assets. Alligator Bioscience will now advance ADC-1013 while seeking a new partner.
Commercial Companies

Deal Watch: Boehringer Teams Up In CNS Disorders Again, This Time With Domain

Following last December’s partnership in CNS with Autifony, BI undertakes a screening collaboration with Domain. Leo maintains its busy deal-making pace, partnering in dermatology with Evotec.

Deals Business Strategies

Alligator CEO Discusses Pipeline Additions, Milestone Expectations And The IO Deal Landscape

Alligator Bioscience’s Per Norlen discusses the latest addition to its pipeline, a first-in-class bispecific tumor-localized antibody targeting the checkpoint inhibitor CTLA-4.

Research & Development Sweden

Alligator CEO Provides Snapshot Of Tumor-Directed IO Pipeline

Following a deal, worth potentially $700m plus, signed in 2015 with Johnson & Johnson’s Janssen Biotech, Swedish biotech Alligator Biosciences AB is well placed to drive its clinical pipeline. During the Biotech Showcase, CEO Per Norlén outlined to Scrip the current status of the pipeline and its plans moving forward, which include having five clinical programs in place by the end of 2019.

ImmunoOncology Cancer
See All

Company Information

  • Industry
  • Biotechnology
    • Large Molecule
      • Antibodies
  • Pharmaceuticals
  • Therapeutic Areas
  • Cancer
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • Scandinavia
          • Sweden
  • Parent & Subsidiaries
  • Alligator Bioscience AB
  • Senior Management
  • Claes Eriksson, CEO
    Charlotte A Russell, MD, PhD, CMO
  • Contact Info
  • Alligator Bioscience AB
    Phone: 46 286 4280
    Medicon Village
    Lund, 223 81
    Sweden
UsernamePublicRestriction

Register